Investor Relations

Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 500,000 TMS treatments to over 14,000 patients struggling with depression.

Recent Filings

For copies of our financial statements and other continuous disclosure filings, please see the Greenbrook TMS profile at SEDAR (System for Electronic Document Analysis and Retrieval) by clicking the link below.

Recent News

September 17, 2020 – Toronto, ON –
GREENBROOK TMS TO HOST INVESTOR WEBCAST ON SEPTEMBER 24, 2020


September 15, 2020 – Toronto, ON –
GREENBROOK TMS REACHES MILESTONE WITH MORE THAN 500,000 TREATMENTS


August 4, 2020 – Toronto, ON –
GREENBROOK TMS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS